/CNW/ - Eat Well Investment Group Inc. (CSE: EWG) (US: EWGFF) (FSE: 6BC0), a leading plant-based food ingredient and CPG company, is pleased to announce it has...
Similar Genomics Systems (OMIC) delivered earnings and revenue surprises of 2.94% and 39.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
TRxADE (MEDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TRxADE (MEDS) delivered earnings and revenue surprises of -66.67% and 8.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
TRxADE (MEDS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
TRxADE (MEDS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend...
TRxADE (MEDS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TRxADE (MEDS) delivered earnings and revenue surprises of 50% and 27.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
TRxADE Health, Inc. (NASDAQ: MEDS) is engaged as a health services IT company, which is focused on digitalizing the entire
TRxADE (MEDS) delivered earnings and revenue surprises of -44.44% and 13.07%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?